BIOMARKER COMPOSITIONS AND METHODS

摘要

Biomarkers can be assessed for diagnostic, therapy-related or prognostic methods to identify phenotypes, such as a condition or disease, or the stage or progression of a disease, select candidate treatment regimens for diseases, conditions, disease stages, and stages of a condition, and to determine treatment efficacy. Circulating biomarkers from a bodily fluid can be used in profiling of physiological states or determining phenotypes. These include nucleic acids, protein, and circulating structures such as vesicles, and nucleic acid-protein complexes.

主权项

1. A method of determining a KRAS nucleotide sequence in a biological sample that comprises one or more microvesicle, comprising:
(a) contacting the biological sample with a binding agent to a microvesicle surface antigen, wherein the microvesicle surface antigen is selected from the group consisting of CD24, Tissue factor, EpCam, B7H3, RAGE, CEA, CD66, and/or TMEM211; (b) isolating nucleic acids from the microvesicles that formed a complex with the binding agent to the microvesicle surface antigen in step (a); and (c) determining a v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) sequence within the nucleic acids isolated in step (b).